Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter
Irvine Biomedical, Inc. · Decision date Sep 3, 2026
What did the FDA decide?
FDA recorded a 30-Day Notice decision coded OK30 on 2026-09-03 for P040014/S052, a supplement to the Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter, a cardiac ablation percutaneous catheter in the cardiovascular specialty under product code LPB. The applicant is Irvine Biomedical, Inc.
The recorded scope is a manufacturing process change: adding an alternate epoxy in the manufacture of the temperature sensor. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. This entry documents that specific change to the device's sensor manufacturing rather than a new approval of the whole catheter system. The source record includes no documents, so the epoxy's identity, supplier qualification data and any testing supporting the change are not available here.
The decision code OK30 is not expanded in the source, and its precise meaning is left unstated. No clinical, performance or labeling conclusions follow from this record.
FDA approval order statement
to add an alternate epoxy in the manufacture of the temperature sensor
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040014/S052
- Regulatory pathway
- PMA supplement
- Applicant
- Irvine Biomedical, Inc.
- Product code
- LPB
- Decision code
- OK30
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Irvine Biomedical, Inc.
- Product code
- LPB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040014 · Original PMA
IBI THERAPY CARDIAC ABLATION SYSTEM ERS/ 1500T RF GENERATOR
P040014/S052 received
Application receipt date recorded by FDA.
P040014/S052 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P040014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Irvine Biomedical, Inc. | PMA approval | Jan 14, 2005 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
| Biosense Webster, Inc. | PMA approval | Aug 11, 2006 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Irvine Biomedical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2375 Morse Ave., Irvine, CA, 92614
Sources and methodology
- Original FDA record: P040014/S052
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records